Global Antacids Market Overview 2023-2028
Over-the-counter medications known as antacids are widely used to offer swift relief from heartburn and indigestion. These medications function by neutralizing excessive stomach acid, the primary culprit behind the discomfort experienced in these conditions. Typically containing alkaline compounds like calcium carbonate, magnesium hydroxide, or aluminum hydroxide, antacids effectively counter the burning sensation and pain caused by heartburn through acid neutralization. While their relief is rapid, it is also short-lived, making them ideal for addressing occasional or mild instances of heartburn. These antacids are available in various forms, including tablets, chewable tablets, liquids, and effervescent powders.
The global antacids market size reached US$ 6.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 8.6 Billion by 2028, exhibiting a growth rate (CAGR) of 4% during 2023-2028.
Global Antacids Market Trends and Drivers:
The surging prevalence of conditions like gastroesophageal reflux disease (GERD), peptic ulcers, and gastritis represents one of the primary factors driving the demand for antacids around the world. It can also be attributed to changing lifestyles, such as irregular dietary habits, sleep patterns, and sedentary lifestyles. Moreover, the easy availability of antacids in pharmacies, supermarkets, and online platforms is favoring the growth of the market. In addition, the increasing number of advertising and marketing campaigns by pharmaceutical companies to promote antacids as a quick and effective remedy is contributing to the market growth. Apart from this, the rising awareness about the benefits of antacids is strengthening the growth of the market.
Global Antacids Market 2023-2028 Analysis and Segmentation:
Top Key Players covered in this report are: Abbott Laboratories, AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline plc, Johnson & Johnson, Pfizer Inc., Procter & Gamble Company, Reckitt Benckiser Group PLC, Sanofi S.A., Sun Pharmaceutical Industries Ltd. and Takeda Pharmaceutical Company Limited.
The report segmented the market on the basis of region, drug class, formulation type and distribution channel.
Breakup by Drug Class:
- Proton Pump Inhibitors
- H2 Antagonist
- Acid Neutralizers
- Pro-Motility Agents
Breakup by Formulation Type:
- Tablet
- Liquid
- Powder
- Others
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Key highlights of the report:
-
- Market Performance (2017-2022)
-
- Market Outlook (2023- 2028)
-
- Porter’s Five Forces Analysis
-
- Market Drivers and Success Factors
-
- SWOT Analysis
-
- Value Chain
-
- Comprehensive Mapping of the Competitive Landscape
If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Services Private Limited.
134 N 4th St. Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800
